Vascular and associated ventricular stiffness is one of the hallmarks of the aging cardiovascular system. Both an increase in reactive oxygen species production and a decrease in nitric oxide (NO) bioavailability contributes to the endothelial dysfunction which underlies this vascular stiffness, independent of other age related vascular pathologies such as atherosclerosis. The activation/upregulation of arginase appears to be an important contributor to age-related endothelial dysfunction by a mechanism that involves substrate (L-arginine) limitation for NOS3 and therefore NO synthesis. Not only does this lead to impaired NO production but contributes to the enhanced production of reactive oxygen species by NOS. While arginase abundance is increased in vascular aging models, it appears that post-translational modification by Snitrosylation of the enzyme enhances its activity as well. The S-nitrosylation is mediated by the induction of NOS2 in the endothelium. Furthermore, arginase activation contributes to agingrelated vascular changes by mechanisms that are not directly related to changes in NO signaling, including polyamine-dependent vascular smooth muscle proliferation and collagen synthesis. Taken together, arginase may represent an as yet elusive target for the modification of age-related vascular and ventricular stiffness contributing to cardiovascular morbidity and mortality.
Introduction
It is no coincidence that factors contributing to longevity are critical in the promotion of cardiovascular health. Whether they include genetic factors such as klotho gene polymorphisms (2, 3) or healthy lifestyles, such as specific diet, exercise and stress reduction, the direct relationship between these factors and cardiovascular risk is now irrefutable. Cardiovascular disease is the leading cause of morbidity and mortality in industrialized countries, and is predicted to increase further in both industrialized and developing countries as population demographics change, even though effective treatments are available that target established cardiovascular risk factors. This apparent incongruity is due to the fact that age itself, even in the absence of established cardiovascular risk factors, is the most important predictor of cardiovascular disease because of age-related changes that occur in the cardiovascular system (52, 53, 65) . Critically, although age itself is an important predictor of cardiovascular events, the vascular changes that accrue with age are highly variable. Hence, it is increasingly recognized that indices of vascular function are better predictors of future cardiovascular events than age itself (65) .
The central aorta dilates with age (52) , while the arterial wall thickness increases even in the absence of atherosclerotic disease (64) mainly as a result of intimal thickening (86) .
Pathologically, aging is associated with elastin depletion and fragmentation, and collagen deposition (68) . These changes result in increased vascular stiffness (48) , central pressure augmentation(67), and manifest themselves clinically as increased systolic and pulse pressures (35, 91) . These vascular changes are important contributors to cardiac changes and vascular-ventricular coupling, and the dysregulation of vital organ blood flow that occurs with aging. Several studies across different populations have clearly demonstrated that increased vascular stiffness is an independent risk factor and predictor of cardiovascular morbidity and mortality (27, 37, 56, 79, 92) . At a cellular and molecular level, the mechanisms that initiate and propagate changes in the aging vasculature are currently the focus of increasing investigation. The histological changes that accrue in the vasculature over many years and decades are generally fixed and irreversible, and are well recognized as significant contributors to increased cardiovascular morbidity and mortality. However, vascular properties, including vascular stiffness, are also modulated acutely and the dynamic component of vascular stiffness particularly influences cardiovascular performance. Acutely, the endothelium also modulates vessel tone (dynamic tone). Endothelial function is now increasingly recognized as extending beyond that of modulating vasomotor tone, for example, via NO production. In addition and importantly, the endothelium is now recognized as an important modulator of chronic changes that accrue in the underlying vascular smooth muscle and extracellular matrix. Interestingly, despite the multitude of potential aging related targets in general and in the vasculature in particular, for the most part, they all converge toward two signaling molecules, NO and reactive oxygen species (ROS) such as the superoxide anion (O 2 -• , which combines with NO to yield peroxynitrite, ONOO -) and related biological oxidants. Here, we review nitroso-redox balance and imbalance in age-related endothelial dysfunction, and we examine the role that the manganese metalloenzyme arginase plays in modulating this balance.
Nitric Oxide in the Aging Endothelium
The first seminal observation pointing to a role for arginase in age-related endothelial dysfunction accompanied the discovery that despite an increase in endothelial NO synthase (NOS3) expression in old rat aorta, NO production and downstream signaling (cGMP) was decreased(14). While a multitude of mechanisms might underlie this somewhat counterintuitive observation, the discovery that ArgI is expressed not only in the liver (where it is a rate limiting enzyme in the urea cycle), but also in endothelial cells (99) , suggested that this enzyme played a role in the impairment of NO signaling. It was reasoned that arginase, which shares L-arginine as a substrate with NO synthase, might compete for limited substrate and thereby regulate the activity of NOS3 in vascular endothelium. This idea was supported by studies of inflammatory cells (macrophages) (63) , gastrointestinal smooth muscle tissue (6) , and penile smooth muscle tissue (19) in which arginase inhibition enhanced NO production and in this way enhanced immune and erectile function, respectively. In order to understand how this process might occur in the endothelium, it is critical to understand not only the enzymology of both NOS3 and arginase, but to understand the compartmentalization of these enzymes within the endothelial cells in which they reside. Furthermore, it is critical to understand how intracellular pools of Larginine are regulated and trafficked so that the mechanisms underlying arginase-NOS3 substrate competition become more apparent.
The NOS3 enzyme exists as a homodimer and its activity is dependent on Ca
2+
dependent CaM binding, requires protoporphyrin IX, tetrahydrobiopterin (BH4), FMN, and FAD as enzyme bound cofactors, and a Zn 2+ ion tetrahedrally ligated by two cysteine residues from each monomer. NOS is regulated at a transcriptional, post-transcriptional, translational and post-translational level (98) . With regard to vascular aging, it is well established that there is a decrease in total NO bioavailability in aged vessels. Age-associated increase in the production of endothelial ROS produced by NADPH oxidase (28) , xanthine oxidase(66) and mitochondrial enzymes (20, 83, 84) , react with NO to form reactive nitrogen species (RNS), thereby quenching/ diminishing bioavailable NO. Reduced NOS3 phosphorylation and activation in response to shear stress is another hallmark of the aging vascular phenotype (76) . Interestingly, SIRT-1 dependent de-acetylation and activation of NOS3 might establish a direct causal connection between calorie restriction (leads to SIRT-1 activation) and NO production(57).
Furthermore, co-factor depletion (particularly tetrahydrobiopterin) might lead to NOS3
uncoupling, which results in production of O2 -• by NOS rather than NO(23). Finally, and from the perspective of the review, limitation of L-arginine substrate by arginase activation/upregulation leads to age-dependent impairment of NO production and might lead to NOS3 uncoupling. The phenomenon of L-Arginine depletion or arginase activation leading to ROS generation has been described for NOS1 (93) and NOS2 (94) and recently in the context of diabetes vascular disease(69) and atherogenesis for NOS3 (70) .
Reciprocal Regulation of NOS by Arginase
Arginase converts L-arginine to L-ornithine and urea, and is found in mammals as two distinct isoforms, ArgI and ArgII, both of which are widely expressed in many tissues, including the cardiovascular system. In extra-hepatic tissues, arginase is thought to be involved in the biosynthesis of L-proline (which is a biosynthetic precursor of collagen) and glutamate, as well as polyamines such as spermine and spermidine (1) 
Arginase Structure, Function, and Inhibitor Design
The X-ray crystal structure of rat ArgI provided the first view of the binuclear manganese cluster required for catalysis (47) , and the subsequently determined structures of human (63) and importantly, the endothelium(7). Furthermore, upregulation of arginase activity has been demonstrated to contribute to the vasoregulatory dysfunction associated with systemic (25, 39, 46, 99) and pulmonary hypertension (43, 61, 96) , diabetes and erectile dysfunction (8, 9) , impaired bronchodilatory function in asthma (62) and vascular dysfunction in aging (7, 71, 90) . These advances have in large measure been a function of the design and synthesis of specific arginase inhibitors such as ABH, BEC, and nor-NOHA.
Implications for Arginase/NOS Regulation
Our initial observations in an aging rat model suggested that ArgI was the predominant but not exclusive isoform upregulated in rat aorta (7) . Furthermore, the cellular source of the upregulated enzyme was confined predominantly but not exclusively to the endothelium. Further studies revealed that upregulated ArgI was indeed confined to the endothelium, and that knockdown of ArgI with specific oligonucleotides could restore NO production and endothelialdependent vasorelaxation in old rat aorta in organ chamber experiments toward that of young rats (90) .
The mechanisms underlying increases in arginase expression and/or activity have not been extensively investigated. Studies in rat aortic vascular smooth muscle demonstrated that interleukin-4 and -13 induced upregulation of ArgI was mediated by the JAK/STAT6 pathway and associated with increased DNA synthesis and cell proliferation(88). In the porcine coronary arterioles, oxidant stress induced by hydrogen peroxide impairs endothelial-dependent dilation.

This effect was associated with increased ArgI DNA and protein expression, and with increased arginase protein synthesis(81). The specific mechanisms underlying post-translational modification and increased arginase activity have also not been clearly defined. Given the interaction between NOS and arginase signaling, we hypothesized that S-nitrosylation of ArgI
might be an important post-translational modification mechanism that regulates its activity. The protein sequence for human ArgI contains three cysteines, C45, C168, and C303, with C303
being very close to R308 and the C-terminal S-shaped tail of arginase. The latter mediates 54% of the inter-subunit interactions to form the active arginase homotrimer (47, 54, 59 Figure 3A ).
Arginase inhibition significantly improves but does not completely reverse age-related endothelial dysfunction. This suggests, not surprisingly, that other mechanisms, both endothelial-dependent and -independent (eg, advanced glycation end-products) contribute to the aged phenotype. Improved endothelial-dependent relaxation following arginase inhibition is associated with increased NO production (Figure 3B). NOS2 was not found in younger vessels but was clearly demonstrated in both the endothelial and non-endothelial components of old vessels (Figure 3C). Increased arginase activity was clearly demonstrated in the endothelial component of old vessels only (Figure 3D). Importantly, this increased arginase activity was completely reversed by 1400W, a specific NOS2 inhibitor (Figure 3D).
So what is the connection between arginase activation, NOS2 induction and aging? It is well established that NOS2 is co-induced in response to inflammatory stimuli mediated by a variety of cytokines (51, 60, 63) in rat and mouse models. While there is limited evidence for
NOS2 expression in cultured endothelial cells treated with pro-inflammatory cytokines and LPS, studies have demonstrated the expression of NOS2 in cultured HUVECs under various conditions including vasoactive stimuli(72), infection with Pseudomonas aeruginosa(4), and upregulation of tissue factor by antiphospholipid antibodies(85). The expression of NOS2 in brain endothelial cells has been shown during embryonic and post-natal development(36), after
ischemic injury (44) , and Alzheimer's disease (29) . While a recent study shows expression of
NOS2 in endothelial cells overlaying stage 3 human atherosclerotic plaque(97), alterations in the expression of NOS2 in aging human aortic endothelial cells is yet to be examined.
Furthermore, a recent study has supported the role that arginase plays in mediating loss of NO and the pathogenesis of endothelial dysfunction in human blood vessels exposed to proinflammatory conditions, specifically inflammatory bowel disease (42) . This, in combination with 
Non-NO-Dependent Effects of Arginase Activation/Upregulation and the Potential
Consequences for Vascular Aging
While the focus of this review has been on the reciprocal regulation of NOS by arginase as a result of substrate limitation, the effects of arginase activation/upregulation might extend well beyond this effect. Ornithine, the product of the conversion of L-arginine to urea is the precursor for the synthesis of primary amino acid, proline and the polyamine-derived amino acids, spermidine and spermine, that could be important in altering vascular properties (30) .
Proline, a primary amino acid that is critical in the synthesis of structural proteins and collagen in particular, is produced by the conversion of ornithine by ornithine aminotransferase.
Furthermore, the overexpression of ArgI or ArgII in endothelial cells is associated with increased production of proline (55) . In addition, the predicted production of collagen in response to stimuli such as TGFB and cyclic strain are dependent on proline formation (31, 32) . Ornithine decarboxylase converts L-ornithine to the polyamine putrescince with the subsequent synthesis of spermidine and spermine. These polyamines are critical in vascular smooth muscle proliferation, with overexpression enhancing and pharmacologic inhibition preventing this proliferative effect (89) . Although the effects of arginase on these parameters have not been directly measured in models of aging, it is conceivable that arginase activation might contribute to age-dependent vascular stiffening and pathology through vascular smooth muscle proliferation, as well as collagen deposition. 
In Summary
